Study to Determine the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Eosinophilic Esophagitis (EoE)

A Phase 3, Randomized, 3-Part Study to Investigate the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Eosinophilic Esophagitis (EoE)

The primary objectives of the study by study part are:

Part A:

To determine the treatment effect of dupilumab compared with placebo in adult and adolescent patients with EoE after 24 weeks of treatment as assessed by histological and clinical measures and to inform/confirm the final sample size determination for Part B.

Part B:

To demonstrate the efficacy of dupilumab treatment compared with placebo in adult and adolescent patients with EoE after 24 weeks of treatment as assessed by histological and clinical measures.

Part C:

To assess the safety and efficacy of dupilumab treatment in adult and adolescent patients with EoE after up to 52 weeks of treatment as assessed by histological and clinical measures.

The secondary objectives of the study are:

• To evaluate the safety, tolerability, and immunogenicity of dupilumab treatment for up to 52 weeks in adult and adolescent patients with EoE
• To explore the relationship between dupilumab concentration and responses in adult and adolescent patients with EoE, using descriptive analyses
• To evaluate the effects of dupilumab on transcriptomic signatures associated with EoE and type 2 inflammation
• To demonstrate the efficacy of dupilumab treatment compared to placebo after 24 weeks and 52 weeks of treatment in adult and adolescent patients with EoE who have previously received swallowed topical corticosteroids

Study Overview

• Status: Completed
• Conditions: Eosinophilic Esophagitis
• Intervention / Treatment: Drug: Placebo; Drug: Dupilumab

• Study Type: Interventional
• Enrollment (Actual): 321
• Phase: Phase 3

Contacts and Locations

Study Locations

• Australia
  • New South Wales
    • Camperdown, New South Wales, Australia, 2050
      • Regeneron Study Site
  • Queensland
    • Woolloongabba, Queensland, Australia, 4102
      • Regeneron Study Site
  • South Australia
    • Elizabeth Vale, South Australia, Australia, 5112
      • Regeneron Study Site
  • Victoria
    • Melbourne, Victoria, Australia, 3052
      • Regeneron Study Site
• Belgium
  • Bruges, Belgium, 8310
    • Regeneron Study Site
  • Edegem, Belgium, 2650
    • Regeneron Study Site
  • Leuven, Belgium, 03000
    • Regeneron Study Site
• Canada
  • Hamilton, Canada, L8S 1G5
    • Regeneron Study Site
  • Ontario
    • London, Ontario, Canada, N6A5W9
      • Regeneron Study Site
    • Ottawa, Ontario, Canada, K1G6S6
      • Regeneron Study Site
  • Quebec
    • Montreal, Quebec, Canada, H3T1C5
      • Regeneron Study Site
• France
  • Pessac, France, 33604 Cedex
    • Regeneron Study Site
  • Toulouse, France, TSA 50032-31059
    • Regeneron Study Site
• Germany
  • Hannover, Germany, 30459
    • Regeneron Study Site
  • Magdeburg, Germany, 39120
    • Regeneron Study Site
  • Munich, Germany, 81675
    • Regeneron Study Site
• Italy
  • Genoa, Italy, 16132
    • Regeneron Study Site
  • Milano, Italy, 20122
    • Regeneron Study Site
  • Naples, Italy, 80100
    • Regeneron Study Site
  • Pisa, Italy, 56124
    • Regeneron Study Site
  • Rome, Italy, 00161
    • Regeneron Study Site
  • Rome, Italy, 00165
    • Regeneron Study Site
  • Rozzano, Italy, 20089
    • Regeneron Study Site
• Netherlands
  • Amsterdam, Netherlands, 1105 AZ
    • Regeneron Study Site
  • Maastricht, Netherlands, 6229HX
    • Regeneron Study Site
  • Nijmegen, Netherlands, 6525GA
    • Regeneron Study Site
• Spain
  • Barcelona, Spain, 08036
    • Regeneron Study Site
  • Madrid, Spain, 28006
    • Regeneron Study Site
  • Ciudad Real
    • Tomelloso, Ciudad Real, Spain, 13700
      • Regeneron Study Site
• Sweden
  • Stockholm, Sweden, 141 86
    • Regeneron Study Site
• Switzerland
  • Zurich, Switzerland, CH-8091
    • Regeneron Study Site
• United Kingdom
  • Whitechapel
    • London, Whitechapel, United Kingdom, E1 1BB
      • Regeneron Study Site
  • Yorkshire
    • Barnsley, Yorkshire, United Kingdom, S752EP
      • Regeneron Study Site
• United States
  • Arizona
    • Phoenix, Arizona, United States, 85016
      • Regeneron Study Site
    • Scottsdale, Arizona, United States, 85259
      • Regeneron Study Site
  • Arkansas
    • Little Rock, Arkansas, United States, 72202
      • Regeneron Study Site
  • California
    • La Jolla, California, United States, 92037
      • Regeneron Study Site
    • Los Angeles, California, United States, 90025
      • Regeneron Study Site
    • Mountain View, California, United States, 94305
      • Regeneron Study Site
    • Orange, California, United States, 92868
      • Regeneron Study Site
    • Rolling Hills Estates, California, United States, 90274
      • Regeneron Study Site
    • San Diego, California, United States, 92123
      • Regeneron Study Site
  • Colorado
    • Aurora, Colorado, United States, 80045
      • Regeneron Study Site
    • Aurora, Colorado, United States, 80220
      • Regeneron Study Site
    • Colorado Springs, Colorado, United States, 80907
      • Regeneron Study Site
    • Lone Tree, Colorado, United States, 80124
      • Regeneron Study Site
  • Connecticut
    • Bristol, Connecticut, United States, 06010
      • Regeneron Study Site
  • Florida
    • Miami, Florida, United States, 33156
      • Regeneron Study Site
    • Saint Petersburg, Florida, United States, 33701
      • Regeneron Study Site
  • Idaho
    • Boise, Idaho, United States, 83706
      • Regeneron Study Site
    • Idaho Falls, Idaho, United States, 83404
      • Regeneron Study Site
  • Illinois
    • Chicago, Illinois, United States, 60611
      • Regeneron Study Site #1
    • Chicago, Illinois, United States, 60611
      • Regeneron Study Site #2
    • Park Ridge, Illinois, United States, 60068
      • Regeneron Study Site
    • Urbana, Illinois, United States, 61801
      • Regeneron Study Site
  • Indiana
    • Indianapolis, Indiana, United States, 46202
      • Regeneron Study Site
  • Iowa
    • Clive, Iowa, United States, 50325
      • Regeneron Study Site
    • Iowa City, Iowa, United States, 52242
      • Regeneron Study Site
  • Kansas
    • Topeka, Kansas, United States, 66606
      • Regeneron Study Site
  • Maryland
    • Hagerstown, Maryland, United States, 21742
      • Regeneron Study Site
  • Massachusetts
    • Boston, Massachusetts, United States, 02111
      • Regeneron Study Site
    • Worcester, Massachusetts, United States, 01655
      • Regeneron Study Site
  • Michigan
    • Ann Arbor, Michigan, United States, 48109
      • Regeneron Study Site
    • Chesterfield, Michigan, United States, 48047
      • Regeneron Study Site
  • Minnesota
    • Plymouth, Minnesota, United States, 55446
      • Regeneron Study Site
    • Rochester, Minnesota, United States, 55905
      • Regeneron Study Site
  • Nebraska
    • Lincoln, Nebraska, United States, 68505
      • Regeneron Study Site
    • Omaha, Nebraska, United States, 68130
      • Regeneron Study Site
  • New York
    • Bronx, New York, United States, 10461
      • Regeneron Study Site
    • Great Neck, New York, United States, 11021
      • Regeneron Study Site
    • Great Neck, New York, United States, 11023
      • Regeneron Study Site
    • New York, New York, United States, 10029
      • Regeneron Study Site
    • New York, New York, United States, 10032
      • Regeneron Study Site
    • New York, New York, United States, 10016
      • Regeneron Study Site
  • North Carolina
    • Chapel Hill, North Carolina, United States, 27599
      • Regeneron Study Site
  • Ohio
    • Cincinnati, Ohio, United States, 45229
      • Regeneron Study Site
    • Dayton, Ohio, United States, 45415
      • Regeneron Study Site
    • Dublin, Ohio, United States, 43016
      • Regeneron Study Site
    • Mentor, Ohio, United States, 44060
      • Regeneron Study Site
  • Pennsylvania
    • Hershey, Pennsylvania, United States, 17033
      • Regeneron Study Site
    • Philadelphia, Pennsylvania, United States, 19104
      • Regeneron Study Site
  • South Carolina
    • Charleston, South Carolina, United States, 29425
      • Regeneron Study Site
    • Greenville, South Carolina, United States, 29615
      • Regeneron Study Site
  • Tennessee
    • Johnson City, Tennessee, United States, 37604
      • Regeneron Study Site
    • Memphis, Tennessee, United States, 38103
      • Regeneron Study Site
  • Texas
    • Dallas, Texas, United States, 75207
      • Regeneron Study Site
    • Fort Worth, Texas, United States, 76104
      • Regeneron Study Site
    • Garland, Texas, United States, 75044
      • Regeneron Study Site
    • Houston, Texas, United States, 77030
      • Regeneron Study Site
    • San Antonio, Texas, United States, 78229
      • Regeneron Study Site
  • Utah
    • Salt Lake City, Utah, United States, 84132
      • Regeneron Study Site
  • Virginia
    • Charlottesville, Virginia, United States, 22903
      • Regeneron Study Site
    • Roanoke, Virginia, United States, 24013
      • Regeneron Study Site
  • Washington
    • Seattle, Washington, United States, 98115
      • Regeneron Study Site
  • Wisconsin
    • Milwaukee, Wisconsin, United States, 53226
      • Regeneron Study Site

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 12 years and older (Child, Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Key Inclusion Criteria (Parts A & B):

• A documented diagnosis of EoE by endoscopic biopsy
• Baseline endoscopic biopsies with a demonstration on central reading of intraepithelial eosinophilic infiltration
• History (by patient report) of an average of at least 2 episodes of dysphagia (with intake of solids) per week in the 4 weeks prior to screening

Key Exclusion Criteria (Parts A & B):

• Body weight ≤40 kg
• Prior participation in a dupilumab clinical trial, or past or current treatment with dupilumab
• Initiation or change of a food-elimination diet regimen or re-introduction of a previously eliminated food group in the 6 weeks prior to screening.
• Other causes of esophageal eosinophilia or the following conditions: hypereosinophilic syndrome and eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome)
• Active Helicobacter pylori infection
• History of achalasia, Crohn's disease, ulcerative colitis, celiac disease, and prior esophageal surgery
• Any esophageal stricture unable to be passed with a standard, diagnostic, 9 to10 mm upper endoscope or any critical esophageal stricture that requires dilation at screening
• History of bleeding disorders or esophageal varices
• Pregnant or breastfeeding women, or women planning to become pregnant or breastfeed during the study

Key Exclusion Criteria (Part C):

• Participants who, during Part A or Part B, developed a serious adverse event (SAE) and/or adverse event (AE) deemed related to study drug, which in the opinion of the investigator could indicate that continued treatment with study drug may present an unreasonable risk for the participant
• Participants who became pregnant during Part A or Part B
• Participants who are prematurely discontinued from study drug due to an AE (patients who are prematurely discontinued from study drug due to lack of efficacy are eligible to enter Part C)
• Patients who did not undergo endoscopy with biopsies prior to receiving rescue treatment

Note: Other inclusion/ exclusion criteria apply

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Quadruple

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Part A: Dupilumab or Placebo; Part A consists of a 24-week double-blind treatment period. Participants will be randomized to receive dupilumab or placebo. At the end of the double-blind treatment visit (week 24), eligible participants may enter Part C. Participants who do not enter Part C will enter a 12-week follow-up period.	Drug: Placebo; Matching placebo; Drug: Dupilumab; Solution for injection administered subcutaneously; Other Names: REGN668; SAR231893; DUPIXENT
Experimental: Part B: Dupilumab or Placebo; Part B consists of a 24-week double-blind treatment period. Participants will be randomized to receive dupilumab dosing regimen 1, dupilumab dosing regimen 2 or placebo. At the end of the double-blind treatment visit (week 24), eligible participants may enter Part C. Participants who do not enter Part C will enter a 12-week follow-up period.	Drug: Placebo; Matching placebo; Drug: Dupilumab; Solution for injection administered subcutaneously; Other Names: REGN668; SAR231893; DUPIXENT
Experimental: Part C: Dupilumab; Part C is a 28-week extended active treatment period. Participants will receive dupilumab dosing regimen 1, dupilumab dosing regimen 2. At the end of the treatment period (week 52), participants will enter a 12-week follow-up period.	Drug: Dupilumab; Solution for injection administered subcutaneously; Other Names: REGN668; SAR231893; DUPIXENT

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Percentage of Participants Achieving Peak Esophageal Intraepithelial Eosinophil Count of ≤6 Eosinophils Per High-power Field (Eos/Hpf) in All Three Regions at Week 24	Esophageal intraepithelial eosinophil count obtained by esophageal endoscopy with biopsies (all 3 esophageal regions: proximal, mid, and distal).	At week 24
Absolute Change From Baseline in Dysphagia Symptom Questionnaire (DSQ) Total Score at Week 24	The DSQ is used to measure the frequency and intensity of dysphagia. DSQ scores can range from 0 to 84, with a lower score indicating less-frequent or less-severe dysphagia.	Baseline and week 24

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Percent Change From Baseline in DSQ Total Score at Week 24	The DSQ is used to measure the frequency and intensity of dysphagia. DSQ scores can range from 0 to 84, with a lower score indicating less-frequent or less-severe dysphagia.	Baseline and week 24
Percentage of Participants Achieving Peak Esophageal Intraepithelial Eosinophil Count of <15 Eos/Hpf in All Three Regions at Week 24	Esophageal intraepithelial eosinophil count obtained by esophageal endoscopy with biopsies (all 3 esophageal regions: proximal, mid, and distal).	At week 24
Normalized Enrichment Score (NES) for the Relative Change From Baseline in the EoE Diagnostic Panel (EDP) at Week 24	NES reflects the degree to which the activity level of a set of disease transcripts is overrepresented at the extremes (top or bottom) of the entire ranked list of transcripts within a sample and is normalized by accounting for the number of transcripts in the set. An NES of 0 indicates no change from baseline, a negative score reflects a reduction in the disease score (more like normal) and a positive score reflects worsening (more active disease).	Baseline and week 24
Percentage of Participants Achieving Peak Esophageal Intraepithelial Eosinophil Count of ≤1 Eos/Hpf in All Three Regions at Week 24	Esophageal intraepithelial eosinophil count obtained by esophageal endoscopy with biopsies (all 3 esophageal regions: proximal, mid, and distal).	At week 24
Absolute Change From Baseline in Severity of EoE Symptoms Other Than Dysphagia as Measured by EoE Symptom Questionnaire (EoE-SQ) at Week 24	The EoE-SQ asks about symptoms that participants with EoE may have (chest pain, stomach pain, burning feeling in chest, food or liquid coming back up into throat, throwing up) during the past 7 days. Response to the severity of each symptom based on the worst experience in the past 7 days is on a scale of 0 to 10 (higher is worse). The EoE-SQ severity score is calculated as the sum of the severity scores from questions 1 to 3 (chest pain, stomach pain, burning feeling in chest), which could range from 0 to 30; a higher score is indicative of more severe symptoms.	Baseline and week 24
Percentage of Participants Who Received Rescue Treatment During the Placebo-controlled, Double-blind Treatment Period at Week 24		At week 24
Absolute Change From Baseline in Esophageal Distensibility Plateau Measured by Functional Lumen Imaging, if Collected, at Week 24		At week 24
Percent Change From Baseline in Peak Esophageal Intraepithelial Eosinophil Count (Eos/Hpf) in All Three Regions at Week 24	Esophageal intraepithelial eosinophil count obtained by esophageal endoscopy with biopsies (all 3 esophageal regions: proximal, mid, and distal). A greater esophageal intraepithelial eosinophil count from baseline indicates worsening disease.	Baseline and week 24
Absolute Change From Baseline in Eosinophilic Esophagitis Histology Scoring System (EoEHSS) Mean Grade Score at Week 24	Severity (grade) and extent (stage) of esophageal abnormalities were scored by blinded, central pathologists using a 4-point scale (0 normal; 3 maximum change) for eight features: eosinophil density, basal zone hyperplasia, eosinophil abscesses, eosinophil surface layering, dilated intercellular spaces, surface epithelial alteration, dyskeratotic epithelial cells and lamina propria fibrosis (absent/present). Higher score indicates greater severity and extent of histological abnormalities.	Baseline and week 24
Absolute Change From Baseline in EoEHSS Mean Stage Score at Week 24	Severity (grade) and extent (stage) of esophageal abnormalities were scored by blinded, central pathologists using a 4-point scale (0 normal; 3 maximum change) for eight features: eosinophil density, basal zone hyperplasia, eosinophil abscesses, eosinophil surface layering, dilated intercellular spaces, surface epithelial alteration, dyskeratotic epithelial cells and lamina propria fibrosis (absent/present). Higher score indicates greater severity and extent of histological abnormalities.	Baseline and week 24
Absolute Change From Baseline in EoE Endoscopic Reference Total Score (EoE-EREFS) at Week 24	EoE esophageal characteristics analyzed based on the EoE-EREFS, a scoring system for inflammatory and remodeling features of disease. The overall total score ranges from 0 to 18 with higher number indicating worse disease.	Baseline and week 24
NES for the Relative Change From Baseline in the Type 2 Inflammation Signature (T2INF) at Week 24	NES reflects the degree to which the activity level of a set of disease transcripts is overrepresented at the extremes (top or bottom) of the entire ranked list of transcripts within a sample and is normalized by accounting for the number of transcripts in the set. An NES of 0 indicates no change from baseline, a negative score reflects a reduction in the disease score (more like normal) and a positive score reflects worsening (more active disease).	Baseline and week 24
Absolute Change From Baseline in Health-related Quality of Life (QoL) Average Score as Measured by EoE Impact Questionnaire (EoE-IQ) at Week 24	The EoE-IQ measures impact of EoE on emotional, social, work & school, & sleep aspects. Participants were asked to respond to 11 questions based on experience living with EoE during past 7 days. Response to each item is on a 5-point scale (1=Not at all [impacted] 2=A little, 3=Somewhat, 4=Quite a bit, 5=Extremely [impacted]). The average score is the sum of non-missing responses divided by the number of items with non-missing responses. The average score can range from 1 to 5; a higher score is indicative of a more negative impact.	Baseline and week 24
Absolute Change From Baseline in Frequency of EoE Symptoms Other Than Dysphagia as Measured by EoE-SQ at Week 24	The EoE-SQ asks about symptoms that participants with EoE may have (chest pain, stomach pain, burning feeling in chest, food or liquid coming back up into throat, throwing up) during the past 7 days. Response to the frequency of each symptom is on a 5-point scale (1 = 'Never', 2 = 'One day', 3 = ' 2-6 days', 4 = 'Once a day', 5 = 'More than once a day'). The EoE-SQ frequency score is calculated as the sum of the frequency scores from the 5 items which could range from 5 to 25; a higher score is indicative of higher frequency of symptoms.	Baseline and week 24
Percentage of Participants Achieving Peak Esophageal Intraepithelial Eosinophil Count of ≤6 Eosinophils Per High-power Field (Eos/Hpf) in All Three Regions at Week 52	Esophageal intraepithelial eosinophil count obtained by esophageal endoscopy with biopsies (all 3 esophageal regions: proximal, mid, and distal).	At week 52
Absolute Change in Dysphagia Symptom Questionnaire (DSQ) Total Score at Week 52	The DSQ is used to measure the frequency and intensity of dysphagia. DSQ scores can range from 0 to 84, with a lower score indicating less-frequent or less-severe dysphagia.	Baseline (of previous study part) and week 52
Percent Change in DSQ Total Score at Week 52	The DSQ is used to measure the frequency and intensity of dysphagia. DSQ scores can range from 0 to 84, with a lower score indicating less-frequent or less-severe dysphagia.	Baseline (of previous study part) and week 52
Absolute Change in EoE Endoscopic Reference Total Score (EoE-EREFS) at Week 52	EoE esophageal characteristics analyzed based on the EoE-EREFS, a scoring system for inflammatory and remodeling features of disease. The overall total score ranges from 0 to 18 with higher number indicating worse disease.	Baseline (of previous study part) and week 52
Percent Change in Peak Esophageal Intraepithelial Eosinophil Count (Eos/Hpf) in All Three Regions at Week 52	Esophageal intraepithelial eosinophil count obtained by esophageal endoscopy with biopsies (all 3 esophageal regions: proximal, mid, and distal). A greater esophageal intraepithelial eosinophil count from baseline indicates worsening disease.	Baseline (of previous study part) and week 52
Absolute Change in EoE Histology Scoring System (EoEHSS) Mean Grade Score at Week 52	Severity (grade) and extent (stage) of esophageal abnormalities were scored by blinded, central pathologists using a 4-point scale (0 normal; 3 maximum change) for eight features: eosinophil density, basal zone hyperplasia, eosinophil abscesses, eosinophil surface layering, dilated intercellular spaces, surface epithelial alteration, dyskeratotic epithelial cells and lamina propria fibrosis (absent/present). Higher score indicates greater severity and extent of histological abnormalities.	Baseline (of previous study part) and week 52
Absolute Change in EoEHSS Mean Stage Score at Week 52	Severity (grade) and extent (stage) of esophageal abnormalities were scored by blinded, central pathologists using a 4-point scale (0 normal; 3 maximum change) for eight features: eosinophil density, basal zone hyperplasia, eosinophil abscesses, eosinophil surface layering, dilated intercellular spaces, surface epithelial alteration, dyskeratotic epithelial cells and lamina propria fibrosis (absent/present). Higher score indicates greater severity and extent of histological abnormalities.	Baseline (of previous study part) and week 52
Percentage of Participants Achieving Peak Esophageal Intraepithelial Eosinophil Count of <15 Eos/Hpf in All Three Regions at Week 52	Esophageal intraepithelial eosinophil count obtained by esophageal endoscopy with biopsies (all 3 esophageal regions: proximal, mid, and distal).	At week 52
Percentage of Participants Achieving Peak Esophageal Intraepithelial Eosinophil Count of ≤1 Eos/Hpf in All Three Regions at Week 52	Esophageal intraepithelial eosinophil count obtained by esophageal endoscopy with biopsies (all 3 esophageal regions: proximal, mid, and distal).	At week 52
Absolute Change in Health-related QOL as Measured by EoE-IQ at Week 52	The EoE-IQ measures impact of EoE on emotional, social, work & school, & sleep aspects. Participants were asked to respond to 11 questions based on experience living with EoE during past 7 days. Response to each item is on a 5-point scale (1=Not at all [impacted] 2=A little, 3=Somewhat, 4=Quite a bit, 5=Extremely [impacted]). The average score is the sum of non-missing responses divided by the number of items with non-missing responses. The average score can range from 1 to 5; a higher score is indicative of a more negative impact.	Baseline (of previous study part) and week 52
Absolute Change From Baseline in Severity of EoE Symptoms Other Than Dysphagia as Measured by EoE-SQ at Week 52	The EoE-SQ asks about symptoms that participants with EoE may have (chest pain, stomach pain, burning feeling in chest, food or liquid coming back up into throat, throwing up) during the past 7 days. Response to the severity of each symptom based on the worst experience in the past 7 days is on a scale of 0 to 10 (higher is worse). The EoE-SQ severity score is calculated as the sum of the severity scores from questions 1 to 3 (chest pain, stomach pain, burning feeling in chest), which could range from 0 to 30; a higher score is indicative of more severe symptoms.	Baseline (of previous study part) and week 52
Absolute Change From Baseline in Frequency of EoE Symptoms Other Than Dysphagia as Measured by EoE-SQ at Week 52	The EoE-SQ asks about symptoms that participants with EoE may have (chest pain, stomach pain, burning feeling in chest, food or liquid coming back up into throat, throwing up) during the past 7 days. Response to the frequency of each symptom is on a 5-point scale (1 = 'Never', 2 = 'One day', 3 = ' 2-6 days', 4 = 'Once a day', 5 = 'More than once a day'). The EoE-SQ frequency score is calculated as the sum of the frequency scores from the 5 items which could range from 5 to 25; a higher score is indicative of higher frequency of symptoms.	Baseline (of previous study part) and week 52
Percentage of Participants Who Received Rescue Medication During the 28-week Extended Active Treatment Period		Baseline (of Part C) to week 28
NES for the Relative Change From Baseline in EoE Diagnostic Panel (EDP) at Week 52	NES reflects the degree to which the activity level of a set of disease transcripts is overrepresented at the extremes (top or bottom) of the entire ranked list of transcripts within a sample and is normalized by accounting for the number of transcripts in the set. An NES of 0 indicates no change from baseline, a negative score reflects a reduction in the disease score (more like normal) and a positive score reflects worsening (more active disease).	Baseline (of previous study part) and week 52
NES for the Relative Change in the Type 2 Inflammation Signature (T2INF) at Week 52	NES reflects the degree to which the activity level of a set of disease transcripts is overrepresented at the extremes (top or bottom) of the entire ranked list of transcripts within a sample and is normalized by accounting for the number of transcripts in the set. An NES of 0 indicates no change from baseline, a negative score reflects a reduction in the disease score (more like normal) and a positive score reflects worsening (more active disease).	Baseline (of previous study part) and week 52
Concentration of Functional Dupilumab in Serum at Week 52		Baseline (of Part C) up to week 52
Incidence of Treatment-emergent Anti-drug Antibody (ADA) Response	Number of treatment-emergent ADA responses to dupilumab reported.	Baseline (of previous study part) up to week 52

Collaborators and Investigators

• Sponsor: Regeneron Pharmaceuticals
• Collaborators: Sanofi
• Investigators: Study Director: Clinical Trial Management, Regeneron Pharmaceuticals

Study record dates

Study Major Dates

• Study Start (Actual): September 24, 2018
• Primary Completion (Actual): September 9, 2021
• Study Completion (Actual): June 7, 2022

Study Registration Dates

• First Submitted: August 14, 2018
• First Submitted That Met QC Criteria: August 14, 2018
• First Posted (Actual): August 16, 2018

Study Record Updates

• Last Update Posted (Actual): June 28, 2023
• Last Update Submitted That Met QC Criteria: June 2, 2023
• Last Verified: June 1, 2023

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Digestive System Diseases; Immune System Diseases; Hypersensitivity, Immediate; Hematologic Diseases; Gastrointestinal Diseases; Gastroenteritis; Hypersensitivity; Esophageal Diseases; Leukocyte Disorders; Eosinophilia; Eosinophilic Esophagitis; Esophagitis
• Other Study ID Numbers: R668-EE-1774; 2018-000844-25 (EudraCT Number)

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No